Amicus Therapeutics Income Statement (2010-2025) | FOLD

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	66.40M	77.41M	79.55M	82.15M	78.72M	80.73M	81.69M	88.10M	86.27M	94.50M	103.50M	115.08M	110.40M	126.67M	141.52M	149.71M	125.25M	154.69M	169.06M	185.21M
Cost of Revenue (Quarter)	6.54M	8.38M	11.70M	7.85M	7.58M	8.20M	13.44M	9.38M	6.94M	9.11M	9.95M	11.32M	13.57M	11.26M	13.28M	14.84M	11.70M	15.22M	19.47M	26.55M
Gross Profit (Quarter)	59.86M	69.03M	67.85M	74.30M	71.13M	72.53M	68.25M	78.71M	79.33M	85.39M	93.56M	103.76M	96.84M	115.41M	128.24M	134.87M	113.55M	139.47M	149.59M	158.66M
Operating items
Depreciation & Amortization - Total (Quarter)
Research & Development (Quarter)	64.12M	63.00M	59.33M	85.60M	81.52M	78.32M	52.97M	63.87M	41.50M	35.15M	40.70M	35.03M	28.33M	24.68M	26.16M	30.19M	27.84M	60.85M	23.41M	23.74M
Selling, General & Administrative (Quarter)	46.73M	42.28M	46.11M	57.60M	58.12M	53.38M	47.27M	54.27M	73.96M	65.42M	65.65M	70.24M	88.03M	73.58M	75.11M	86.67M	91.83M	84.54M	90.04M	117.08M
Restructuring Costs (Quarter)													6.04M		3.14M
Other Operating Expenses (Quarter)	-0.47M	-1.02M	-3.29M	-1.73M	1.19M	-0.12M	-0.57M	-1.58M	-0.25M	-0.34M	-2.00M						1.84M	3.55M	1.87M	1.90M
Operating Expenses (Quarter)	112.92M	107.87M	110.25M	146.45M	146.47M	133.15M	102.09M	121.04M	116.96M	104.25M	110.58M	107.45M	124.56M	100.44M	106.58M	118.90M	121.50M	148.94M	115.33M	142.72M
Operating Income (Quarter)	-53.05M	-38.83M	-42.40M	-72.15M	-75.34M	-60.61M	-33.84M	-42.33M	-37.64M	-18.86M	-17.02M	-3.69M	-27.72M	14.97M	21.66M	15.97M	-7.95M	-9.47M	34.27M	15.95M
EBIT (Quarter)	-53.05M	-38.83M	-42.40M	-72.15M	-75.34M	-60.61M	-33.84M	-42.33M	-37.64M	-18.86M	-17.02M	-3.69M	-27.72M	14.97M	21.66M	15.97M	-7.95M	-9.47M	34.27M	15.95M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)	0.17M	0.05M	0.11M	0.19M	0.13M	0.36M	0.56M	1.97M	2.20M	1.74M	1.47M	1.67M	1.54M	1.37M	1.08M	1.42M	0.81M	0.84M	0.83M	0.83M
Other Non Operating Income (Quarter)	-3.20M	0.23M	0.24M		1.90M	7.27M	13.63M	-18.63M	-5.94M	-10.90M	3.83M	-0.89M	-4.97M	-3.72M	-3.26M	2.50M	0.55M	1.01M	10.89M	-12.45M
Non Operating Income (Quarter)	-3.20M	0.23M	0.24M	-0.17M	1.90M	7.27M	13.63M	-18.63M	-5.94M	-10.90M	3.83M	-2.88M	-4.97M	-3.72M	-3.26M	2.50M	0.55M	1.01M	10.89M	-2.21M
Net income details
EBT (Quarter)	-64.08M	-46.70M	-50.48M	-80.30M	-81.45M	-61.25M	-29.26M	-70.08M	-53.22M	-40.52M	-24.70M	-31.66M	-43.58M	0.11M	6.79M	7.93M	-18.05M	-19.18M	34.27M	3.14M
Tax Provisions (Quarter)	1.58M	4.53M	-0.18M	2.98M	3.81M	0.91M	4.02M	-14.21M	-0.29M	2.71M	-3.13M	2.18M	4.84M	15.80M	13.51M	-6.80M	3.64M	5.24M	16.97M	1.45M
Profit After Tax (Quarter)	-65.66M	-51.23M	-50.29M	-83.28M	-85.26M	-62.16M	-33.29M	-55.87M	-52.93M	-43.23M	-21.58M	-33.84M	-48.42M	-15.70M	-6.73M	14.74M	-21.69M	-24.42M	17.31M	1.69M
Income from Continuing Operations (Quarter)	-65.66M	-51.23M	-50.29M	-83.28M	-85.26M	-62.16M	-33.29M	-55.87M	-52.93M	-43.23M	-21.58M	-33.84M	-48.42M	-15.70M	-6.73M	14.74M	-21.69M	-24.42M	17.31M	1.69M
Consolidated Net Income (Quarter)	-65.66M	-51.23M	-50.29M	-83.28M	-85.26M	-62.16M	-33.29M	-55.87M	-52.93M	-43.23M	-21.58M	-33.84M	-48.42M	-15.70M	-6.73M	14.74M	-21.69M	-24.42M	17.31M	1.69M
Income towards Parent Company (Quarter)	-65.66M	-51.23M	-50.29M	-83.28M	-85.26M	-62.16M	-33.29M	-55.87M	-52.93M	-43.23M	-21.58M	-33.84M	-48.42M	-15.70M	-6.73M	14.74M	-21.69M	-24.42M	17.31M	1.69M
Net Income towards Common Stockholders (Quarter)	-65.66M	-51.23M	-50.29M	-83.28M	-85.26M	-62.16M	-33.29M	-55.87M	-52.93M	-43.23M	-21.58M	-33.84M	-48.42M	-15.70M	-6.73M	14.74M	-21.69M	-24.42M	17.31M	1.69M
Additional items
EPS (Basic) (Quarter)		-0.19		-0.31	-0.30			-0.19	-0.18	-0.15	-0.07	-0.11	-0.16	-0.05	-0.02	0.05	-0.07	-0.08	0.06	0.01
EPS (Weighted Average and Diluted) (Quarter)		-0.19		-0.31	-0.30			-0.19	-0.18	-0.15	-0.07	-0.11	-0.16	-0.05	-0.02	0.05	-0.07	-0.08	0.06	0.01
Shares Outstanding (Weighted Average) (Quarter)		265.38M		271.42M	288.48M			289.06M	291.34M	292.07M	293.31M	295.16M	302.90M	303.77M	303.79M	304.38M	307.69M	307.97M	308.14M	308.36M
Shares Outstanding (Diluted Average) (Quarter)		266.40M		271.42M	288.48M			289.06M	291.34M	292.07M	293.31M	295.16M	302.90M	303.34M	303.79M	304.38M	307.69M	308.25M	308.14M	308.36M
EBITDA (Quarter)	-53.05M	-38.83M	-42.40M	-72.15M	-75.34M	-60.61M	-33.84M	-42.33M	-37.64M	-18.86M	-17.02M	-3.69M	-27.72M	14.97M	21.66M	15.97M	-7.95M	-9.47M	34.27M	15.95M
Interest Expenses (Quarter)	7.99M	8.15M	8.16M	8.16M	8.15M	8.26M	9.62M	11.10M	11.84M	12.49M	12.99M	12.83M	12.44M	12.51M	12.69M	11.96M	11.46M	11.56M	11.71M	11.43M
Tax Rate (Quarter)	-2.47%	-9.69%	0.36%	-3.71%	-4.68%	-1.49%	-13.75%	20.28%	0.54%	-6.70%	12.66%	-6.90%	-11.10%	14,634.26%	199.17%	-85.77%	-20.18%	-27.31%	49.51%	46.23%

Research Tools

Amicus Therapeutics Income Statement (2010-2025) | FOLD

Create an account

Sign In

Reset Password